NCT05281601 - AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions

SARS-CoV-2

Interventions

DRUG

AZD7442

"IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion."

Trial Locations (11)

3000

Research Site, Leuven

11794

Research Site, Stony Brook

20007

Research Site, Washington D.C.

29464

Research Site, Mt. Pleasant

60590

Research Site, Frankfurt am Main

80045

Research Site, Aurora

83404

Research Site, Idaho Falls

90806

Research Site, Long Beach

02903

Research Site, Providence

30130-100

Research Site, Belo Horizonte

SO16 6YD

Research Site, Southampton